非瓣膜性心房颤动与脑梗死的相关因素分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (678 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relationship among the mean platelet volume, fibrinogen and left atrial size and cerebral infarction in patients with nonvalvular atrial fibrillation (AF). Methods: One hundred and sixty-five patients with AF were divided into AF with and without cerebral infarction diagnosed with computed tomography (CT) and/or magnetic resonance imaging (MRI). CHA2DS2-vasc score, mean platelet volume, plasma fibrinogen, left atrial size, blood pressure, serum lipid level and renal function were detected in the enrolled population. Results: Compared with the patients without cerebral infarction, the AF patients with cerebral infarction showed higher level of CHA2DS2-vasc score (P<0.001), plasma fibrinogen (P=0.002), mean platelet volume (P<0.001), fasting plasma glucose (P=0.034), lipoprotein (a) (P=0.017) and larger left atrial size (P<0.001). After adjustment of multiple traditional cardiovascular risk factors, logistic regression analysis showed that mean platelet volume, plasma fibrinogen, left atrial size and CHA2DS2-vasc score were independent risk factors for AF-related cerebral infarction. Conclusion: Except CHA2DS2-vasc score, the combined index of mean platelet volume, plasma fibrinogen and left atrial size may also play an important role in predicting the occurrence of cerebral infarction in patients with AF.

Received: 14 July 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Jianlei1
	YAN Peiyuan2
	WANG Haiqing1

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I1/44

[1] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused up- date of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the spe- cial contribution of the European Heart Rhythm Associa- tion[J]. Europace, 2012, 14(10): 1385-1413.
[2] Bouzas-Mosquera A, Broull FJ, varez-Garc N, et al. Left atrial size and risk for all-cause mortality and ischemic stroke[J]. CMAJ, 2011, 183(10): E657-664.
[3] Pisters R, Lane DA, Marin F, et al. Stroke and thromboem- bolism in atrial fibrillation[J]. Circ J, 2012, 76(10): 2289- 2304.
[4] Bath P, Algert C, Chapman N, et al. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease[J]. Stroke, 2004, 35 (3): 622-626.
[5] Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography抯 Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology[J]. J Am Soc Echocardiogr, 2005, 18(12): 1440- 1463.
[6] Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics[J]. Circulation, 2011, 124(18): 1982-1993.
[7] Abhayaratna WP, Seward JB, Appleton CP, et al. Left atrial size: physiologic determinants and clinical applications[J]. J Am Coll Cardiol, 2006, 47(12): 2357-2363.
[8] Van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes[J]. Arterioscler Thromb Vasc Biol, 1999, 19(3): 672-679.
[9] Khode V, Sindhur J, Kanbur D, et al. Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: A case control study[J]. J Cardiovasc Dis Res, 2012, 3(4): 272- 275.
[10] Turfan M, Erdogan E, Ertas G, et al. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrilla- tion patients[J]. Blood Coagul Fibrinolysis, 2013, 24(1): 55-58.
[11] Loukas M, Dabrowski M, Wagner T, et al. Fibrinogen and smooth muscle cell detection in atherosclerotic plaques from stable and unstable angina-an immunohistochemical study [J]. Med Sei Monit, 2002, 8(4): BR144-148.
[12] Gouni-Berthold I, Berthold HK. Lipoprotein(a): current per- spectives[J]. Curr Vasc Pharmacol, 2011, 9(6): 682-692.
[13] Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coro- nary heart disease, stroke, and nonvascular mortality[J]. JAMA, 2009, 302(4): 412-423.
[14] Wityk RJ, Kittner SJ, Jenner JL, et al. Lipoprotein(a) and the risk of ischemic stroke in young women[J]. Atheros- clerosis, 2000, 150(2): 389-396.
[15] 陈昆明, 赵尖萍. 急性脑梗塞患者致炎细胞因子和早期神经功能恶化的关系[J]. 温州医学院学报, 2004, 34(4): 250-252.